Surgery Websites
Breast Care Surgery »  Faculty »  Breast Care Surgeons »  Laura J. Esserman, M.D., M.B.A.
Laura J. Esserman, M.D., M.B.A.

Laura J. Esserman, M.D., M.B.A.

Professor of Surgery and Radiology
Division of General Surgery
Alfred A. de Lorimier Endowed Chair in General Surgery
Director, UCSF Carol Franc Buck Breast Care Center
Chief, Section of Breast Care Surgery

Contact Information

Open Popup
  • 1974-77, Harvard University, A.B.
  • 1978-83, Stanford University, M.D.
  • 1983-85, Stanford University School of Medicine, Resident, General Surgery
  • 1988-90, Stanford University School of Medicine, Resident, General Surgery
  • 1990-91, Stanford University School of Medicine, Chief Resident, General Surgery
  • 1985-88, Stanford University School of Medicine, Postdoctoral Fe, Oncology, Medical
  • 1991-93, Stanford University, M.B.A.
  • American Board of Surgery - General Surgery - 1992
  • UCSF Center of Excellence for Breast Cancer Care
  • UCSF Carol Frank Buck Breast Care Center
  • UCSF Helen Diller Comprehensive Cancer Center
  • Breast Diseases
  • Breast Neoplasms
  • Cancer Vaccines
  • Genes
  • Intraductal Carcinoma
  • Male
  • Mammary
  • Mastectomy
  • Noninfiltrating Carcinoma Lobular
  • Oncogenes
  • Precancerous Conditions
  • Segmental
  • Tumor Suppressor
  • Ultrasonography
  • BRCA1 Protein
  • BRCA2 Protein
  • Infiltrating Duct Carcinoma

 

Dr. Laura Esserman, M.D., M.B.A is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996.  She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center's multidisciplinary programs. The program is comprised of 69 faculty members who represent 16 academic specialties and is internationally recognized and well-established with major initiatives in epidemiology, genetics, biology, therapeutics, and clinical cancer care.  She is a professor of Surgery & Radiology at UCSF and Associate Director of the UCSF Helen Diller Family Comprehensive Cancer Center where she has founded and led the program in Translational Informatics. As part of this program, her research has focused on bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.

 

Dr. Esserman received her Bachelor's degree in History of Science from Harvard University and completed her M.D. at Stanford University. She completed her surgery residency and oncology fellowship at Stanford University Medical Center.  After her training, she joined the faculty at Stanford and received a Hartford fellowship to attend Stanford Business School where she received her M.B.A. in 1993.  She then joined the faculty at the University of California, San Francisco.  She has worked at UCSF to develop interdisciplinary teams of clinicians and researchers to bring the best care to patients and find the best platform to integrate translational research and improve the delivery of breast cancer care.

 

Dr. Esserman has been a leader in the I-SPY TRIAL collaboration, a National Cancer Institute's (NCI) Center for Bioinformatics and SPORE program. In 2005, she received the NCI SPORE Investigator of the Year Award, an internationally recognized honor and designation.  As the Primary Investigator of a Department of Defense-funded Center of Excellence grant, she has also brought together an extraordinary, multidisciplinary group of investigators and health care industry partners to work on critical problems concerning the quality of breast cancer care. Highly respected by her peers, Dr. Esserman was named to the list of U.S. News "America's Top Doctors," a distinction reserved for the top 1% of physicians in the nation for a given specialty.

 

Dr. Esserman is a prolific writer with numerous publications in peer-reviewed journals covering all aspects of breast health including information systems, immunology, decision making, health policy and the use of imaging. She speaks extensively at public and private forums within the U.S. and internationally.  Overall, Dr. Esserman's research and writing tends to focus on the goal of giving patients better access to accurate information so that they can become partners in their health care.

Most recent publications from a total of 305
  1. Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ. A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. NPJ Breast Cancer. 2019; 5:17. View in PubMed
  2. Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, Esserman LJ, Hylton NM. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL. J Magn Reson Imaging. 2019 Apr 26. View in PubMed
  3. Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. NPJ Breast Cancer. 2019; 5:12. View in PubMed
  4. Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E. A response to "Personalised medicine and population health: breast and ovarian cancer". Hum Genet. 2019 Mar; 138(3):287-289. View in PubMed
  5. Esserman LJ, Varma M. Should we rename low risk cancers? BMJ. 2019 Jan 23; 364:k4699. View in PubMed
  6. Ozanne EM, Howe R, Mallinson D, Esserman L, Van't Veer LJ, Kaplan CP. Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women. J Genet Couns. 2019 Jan 21. View in PubMed
  7. Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ Breast Cancer. 2019; 5:2. View in PubMed
  8. Esserman LJ, LaCroix AZ. Precision risk-based screening might maximize benefit and minimize harm. Nat Rev Clin Oncol. 2018 Nov; 15(11):661-662. View in PubMed
  9. Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial. J Magn Reson Imaging. 2018 Oct 22. View in PubMed
  10. Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer. 2018; 4:31. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Laura J. Esserman, M.D., M.B.A.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

Site Directory
    X